| Mucopolysaccharidoses type I gene therapy SC Hurt, PI Dickson, DT Curiel Journal of inherited metabolic disease 44 (5), 1088-1098, 2021 | 8 | 2021 |
| Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I SC Hurt, MU Vera, SQ Le, S Kan, Q Bui, PI Dickson Molecular Genetics and Metabolism Reports 38, 101036, 2024 | | 2024 |
| Elucidating expression of a corrective enzyme for mucopolysaccharidoses type I through administration of an adenoviral vector targeted to endothelial cells S Hurt, SQ Le, A Sorensen, DT Curiel, PI Dickson Molecular Genetics and Metabolism 141 (2), 107890, 2024 | | 2024 |
| Anti-IDUA IgG alters cortical bone structure of mucopolysaccaridosis type I mice treated with intravenous enzyme replacement therapy S Hurt, SQ Le, S Kan, M Brodt, PI Dickson Molecular Genetics and Metabolism 141 (2), 107891, 2024 | | 2024 |
| Elucidating expression of a corrective enzyme for MPS I through administration of an adenoviral vector targeted to endothelial cells S Hurt, SQ Le, S Mendonça, A Sorensen, DT Curiel, PI Dickson Molecular Genetics and Metabolism 138 (2), 107161, 2023 | | 2023 |
| An adenoviral mediated gene therapy for mucopolysaccharidosis type I S Hurt, SQ Le, S Mendonca, P Dickson, DT Curiel Molecular Genetics and Metabolism 135 (2), S60, 2022 | | 2022 |
David T. CurielWashington University School of MedicineVerified email at wustl.edu
